

Volume 30 (Supplement 2) May 2003



THE CANADIAN JOURNAL OF

# Neurological Sciences

LE JOURNAL CANADIEN DES

# Sciences Neurologiques

AN INTERNATIONAL JOURNAL / UN JOURNAL INTERNATIONAL

38th MEETING OF THE  
CANADIAN CONGRESS OF  
NEUROLOGICAL SCIENCES




## ABSTRACTS

*The official Journal of:* The Canadian Neurological Society, The Canadian Neurosurgical Society,  
The Canadian Society of Clinical Neurophysiologists, The Canadian Association of Child Neurology

# REMINYL:<sup>\*</sup> FOR THE TREATMENT OF ALZHEIMER'S DISEASE

†† Now on provincial formularies  
for Ontario, Quebec, Alberta,  
Saskatchewan and Manitoba



## Unique proposed mode of action:

Cholinesterase inhibition and nicotinic modulation<sup>1,2†</sup>

**REMINYL:**  
The difference may be  
nicotinic modulation<sup>†</sup>

More than just cholinesterase inhibition, REMINYL enhances the action of acetylcholine through binding to an allosteric site on the nicotinic receptors<sup>1,2†</sup>

† Based on *in vitro* data. The clinical relevance to humans is unknown. The majority of common side effects occurred during the dose-escalation period and were primarily gastrointestinal. During maintenance therapy, the most common side effects were: REMINYL 16 mg/day-nausea (4%) and diarrhea (5%); REMINYL 24 mg/day-nausea (6%), vomiting (6%) and anorexia (5%).


REMINYL (galantamine hydrobromide) is indicated for the symptomatic treatment of patients with mild to moderate dementia of the Alzheimer's type. REMINYL has not been studied in controlled clinical trials for longer than 6 months. There is no evidence that galantamine alters the course of the underlying dementing process.


### References:

1. REMINYL<sup>®</sup> (galantamine hydrobromide) Product Monograph, JANSSEN-ORTHO Inc., March 6, 2002.
2. Maelicke A, Albuquerque EX. *Eur J Pharmacol* 2000;393:165-170.

†† Exception drug status.

RMJA021007B



 JANSSEN-ORTHO

19 Green Belt Drive  
Toronto, ON M3C 1L9  
www.janssen-ortho.com

© 2002 JANSSEN-ORTHO Inc.  
\* All trademark rights used under license

 **Reminyl**<sup>®</sup>  
Galantamine hydrobromide tablets

For living – each day